Advertisement
Canada markets close in 4 hours 8 minutes
  • S&P/TSX

    21,852.78
    -158.94 (-0.72%)
     
  • S&P 500

    5,054.05
    -16.50 (-0.33%)
     
  • DOW

    38,325.15
    -178.54 (-0.46%)
     
  • CAD/USD

    0.7287
    -0.0034 (-0.46%)
     
  • CRUDE OIL

    82.71
    -0.65 (-0.78%)
     
  • Bitcoin CAD

    88,710.88
    -2,577.20 (-2.82%)
     
  • CMC Crypto 200

    1,404.59
    -19.51 (-1.37%)
     
  • GOLD FUTURES

    2,339.10
    -3.00 (-0.13%)
     
  • RUSSELL 2000

    1,990.85
    -11.79 (-0.59%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ

    15,676.81
    -19.83 (-0.13%)
     
  • VOLATILITY

    15.98
    +0.29 (+1.85%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6817
    -0.0019 (-0.28%)
     

Analyst Recommendations for Ignyta and Its Peers in January 2018

Analyst Recommendations for Ignyta and Its Peers in January 2018

Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.